Adaptimmune Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Net Income	-113.87	-165.46	-158.09	-130.09	-137.17	-95.51	-70.14	-71.58	-36.79	-11.6
Depreciation & Amortization	9.84	6.08	6.57	7.59	8.01	7.81	5.42	3.29	0.74	0.24
Share-Based Compensation	11.77	18.24	20.63	10.41	11.05	16.2	10.8	8.82	7.08	0.33
Other Operating Activities	-48.62	-0.63	141.62	58.49	5.6	-32.89	-0.4	11.3	-15.42	47.86
Operating Cash Flow	-140.88	-141.77	10.73	-53.59	-112.51	-104.39	-54.32	-48.17	-29.67	36.84
Capital Expenditures	-4.68	-29.5	-8.57	-2.34	-1.59	-3.91	-24.09	-11.51	-4.96	-1.37
Acquisitions	45.26	0	0	0	0	0	0	0	0	0
Change in Investments	135.03	118.88	84.58	-276.02	98.02	-12.75	-101.62	30.54	-53.88	0
Other Investing Activities	0.93	-0.24	-0.21	-0.57	-1.48	-0.8	-0.37	-1.28	-	-
Investing Cash Flow	176.54	89.14	75.8	-278.92	94.95	-17.46	-126.08	17.76	-58.84	-1.37
Share Issuance / Repurchase	0.88	12.87	3.29	340.05	0.37	102.69	103.57	0.02	175.99	16
Debt Issued / Paid	0	0	0	0	0	0	0	0	0	-1.29
Other Financing Activities	-	-	-	-	-	-	-	-	98.87	-
Financing Cash Flow	0.88	12.87	3.29	340.05	0.37	102.69	103.57	0.02	274.86	14.71
Exchange Rate Effect	0.88	-2.3	0.37	-0.96	-0.37	3.34	2.33	-5.58	-8.49	1
Net Cash Flow	37.42	-42.06	90.18	6.58	-17.57	-15.82	-74.5	-35.98	177.87	51.18
Free Cash Flow	-145.56	-171.27	2.16	-55.93	-114.1	-108.3	-78.41	-59.67	-34.62	35.47
Free Cash Flow Margin	-241.47%	-630.86%	35.05%	-1413.14%	-10169.25%	-182.00%	-207.25%	-420.30%	-350.76%	4299.27%
Free Cash Flow Per Share	-0.72	-1.06	0.01	-0.39	-1.09	-1.11	-0.89	-0.84	-0.97	1.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).